Treatment of rheumatoid arthritis with humanized anti-interleukin-6 receptor antibody: a multicenter, double-blind, placebo-controlled trial.

By N. Nishimoto, K. Yoshizaki, N. Miyasaka, Kazuhiko Yamamoto, S. Kawai, T. Takeuchi, J. Hashimoto, J. Azuma, T. Kishimoto. Arthritis & Rheumatism, 2004

786 citations recorded by the source corpus.

Subfields: Oncology, Rheumatology

View Paper: https://www.semanticscholar.org/paper/267200a4d3726cffa038f8280ebfee6388f301e7

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

In Oncology

1. Markus F. Neurath
2. B. K. Pedersen
3. S. Rose‐John

In Rheumatology

1. T. Kishimoto
2. N. Nishimoto
3. B. K. Pedersen
4. Markus F. Neurath

Citations in the corpus

• Interleukin-6 in aging and chronic disease: a magnificent pathway. (2006, background): “Pilot and full-scale randomized clinical trials are currently being conducted for the treatment of Crohn’s disease (33), rheumatoid arthritis (149), moderately active systemic lupus erythematosus (150), and Castelman’s disease (151,152).”
• Role of myokines in exercise and metabolism. (2007, background): “Blocking IL-6 in clinical trials with patients with rheumatoid arthritis leads to enhanced cholesterol and plasma glucose levels, indicating that functional lack of IL-6 may lead to insulin resistance and an atherogenic lipid profile rather than the opposite (14, 45, 46).”
• The anti-inflammatory effect of exercise. (2005, background): “In contrast, anti-IL-6 receptor treatment induced increase of both highdensity and low-density lipoprotein (86).”
• Study of active controlled monotherapy used for rheumatoid arthritis, an IL-6 inhibitor (SAMURAI): evidence of clinical and radiographic benefit from an x ray reader-blinded randomised controlled trial of tocilizumab (2007, result): “Although this was an open-label study for clinical efficacy endpoints, the results of previous phase II studies 21 22 were confirmed.”
• Muscles and their myokines (2011, background): “In addition, changes in lipid profiles were also seen in patients with rheumatoid arthritis receiving IL-6 blocking treatment (Nishimoto et al., 2004; Maini et al., 2006; Smolen et al., 2008).”